{
  "pathway_name": "meningioma-clinical-pathways-v2-2024-508h",
  "original_file": "meningioma-clinical-pathways-v2-2024-508h_extracted.json",
  "processed_at": "2025-03-29T00:47:33.451255",
  "complete_summary": {
    "response": "# COMPREHENSIVE MENINGIOMA CLINICAL PATHWAY\n\n## I. INITIAL EVALUATION AND DIAGNOSIS\n\n### A. Initial Clinical Assessment\n- Complete neurological examination\n- Evaluate for symptoms of increased intracranial pressure\n- Assess for hereditary syndromes (particularly neurofibromatosis type 2)\n  - Consider Genetics referral when appropriate\n\n### B. Imaging Assessment\n- **Primary Imaging**: MRI with and without contrast\n- **Alternative**: CT with contrast if MRI contraindicated\n- Determine if findings are consistent with meningioma characteristics\n- **Next Steps**:\n  - If consistent with meningioma \u2192 Refer to Neurosurgery or Neurology\n  - If inconclusive \u2192 Consider additional imaging or follow-up\n\n### C. Treatment Candidacy Determination\n- **If candidate for treatment** \u2192 Proceed to treatment evaluation\n- **If not a candidate** \u2192 Implement surveillance protocol\n  - Monitor for changes in tumor size or symptoms\n  - Case should be discussed through local tumor board or National TeleOncology CNS Virtual Tumor Board\n\n## II. TREATMENT DECISION PATHWAY\n\n### A. Surgical Management\n- **Surgical Candidacy Assessment**:\n  - If candidate for surgery \u2192 Perform resection and post-resection MRI\n  - If not a surgical candidate \u2192 Refer to Radiation Oncology and Neuro-oncology\n\n### B. Pathological Evaluation\n- Confirm meningioma diagnosis\n- WHO classification grading\n- **Molecular Testing**:\n  - TERT mutation testing\n  - FISH for 22q/CDKN2A/B deletion\n- Neuropathology consultation recommended for challenging cases\n- **Simpson Grading System**:\n  - Grades 1-3: Gross total resection\n  - Grades 4-5: Subtotal resection\n\n### C. Post-Surgical Management by WHO Grade\n\n#### WHO Grade 1\n- **With residual tumor** \u2192 Refer to Radiation Oncology\n- **Without residual tumor** \u2192 MRI surveillance\n\n#### WHO Grade 2\n- Refer to Radiation Oncology\n- **With residual tumor** \u2192 Adjuvant radiotherapy\n- **Without residual tumor** \u2192 Patient preference:\n  * Adjuvant radiotherapy, OR\n  * MRI surveillance\n\n#### WHO Grade 3\n- Refer to Radiation Oncology for radiotherapy\n- Refer to Neuro-oncology for systemic therapy consideration\n- Consider clinical trial enrollment\n\n## III. MOLECULAR TESTING PROTOCOL\n\n### A. Eligibility and Specimen Requirements\n- **Patient Population**: All meningioma patients regardless of histology\n- **Required Specimen**: Tumor tissue\n\n### B. Testing Algorithm\n1. **Standard Molecular Testing**:\n   - TERT promoter mutation testing (required)\n\n2. **Chromosomal Analysis** (select ONE):\n   - **FISH Analysis** (preferred option)\n     - Target: CDKN2A/B homozygous loss\n     \n   - **Microarray Analysis** (alternative)\n     - Test: Chromosomal microarray (Oncoscan FFPE)\n     - Note: If microarray is performed, FISH testing is not indicated\n\n### C. Testing Considerations\n- FISH is preferred in most clinical scenarios\n- Local VA or locally contracted vendor recommended\n- NPOP coverage not available for these molecular tests\n\n## IV. MONITORING AND FOLLOW-UP\n\n- **Surveillance Protocol**:\n  - Regular MRI brain with and without contrast\n  - Monitor for symptomatic changes and radiographic progression\n  - Surveillance interval may increase after 5 years without recurrence\n\n## V. SPECIAL CONSIDERATIONS\n\n### A. Clinical Trials\n- Should always be considered as a treatment option\n- For assistance finding appropriate trials, email CancerClinicalTrials@va.gov\n\n### B. Multidisciplinary Care\n- Complex cases should be presented at tumor boards\n- National TeleOncology consult available if local VA Neuro-oncology unavailable\n\n### C. VA Disability Benefits Eligibility (Presumptive Service Connection)\n1. **Atomic Veterans Exposed to Ionizing Radiation**\n   - Brain cancer (including meningioma) is presumptively service-connected\n\n2. **Gulf War and Post-9/11 Veterans**\n   - Eligible if served on/after September 11, 2001 in:\n     * Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, Yemen\n   - OR if served in Southwest Asia theater or Somalia on/after August 2, 1990\n     * Southwest Asia theater includes: Iraq, Kuwait, Saudi Arabia, neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, UAE, Oman, Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea, and airspace above these locations\n\nThis clinical pathway provides a structured approach to the diagnosis, treatment, and monitoring of meningiomas while emphasizing molecular characterization and multidisciplinary management, with special considerations for the Veteran population.",
    "thinking": "I need to synthesize a comprehensive clinical pathway summary for meningioma based on the provided page analyses. Let me organize the information into a cohesive, clinically relevant document that would serve as an authoritative reference for healthcare providers.\n\nFrom the information provided, I can see:\n- Page 2 contains a table of contents (not much detail provided)\n- Page 3 discusses VA disability benefit eligibility for veterans with meningioma\n- Page 4 outlines the initial evaluation and management pathway for meningioma\n- Page 5 describes molecular testing approaches for meningioma\n\nI'll create a structured document that incorporates all these elements, focusing on the clinical pathway aspects while acknowledging the VA-specific information on presumptive conditions. I'll organize it into logical sections with clear decision points.\n\n# COMPREHENSIVE MENINGIOMA CLINICAL PATHWAY\n\n## Introduction\nMeningiomas are tumors that arise from the meninges, the membranes that surround the brain and spinal cord. They account for approximately 36% of all primary central nervous system tumors. This clinical pathway provides a structured approach to the evaluation, diagnosis, treatment, and follow-up of patients with meningioma.\n\n## I. Initial Evaluation and Diagnosis\n\n### A. Clinical Assessment\n- Complete history and physical examination with particular attention to neurological symptoms\n- Assessment for signs/symptoms of increased intracranial pressure\n- Evaluation for hereditary syndromes (particularly neurofibromatosis type 2)\n  - Referral to Genetics when appropriate\n\n### B. Imaging Assessment\n- **Standard Imaging**: MRI with and without contrast\n- **Alternative Imaging**: CT with contrast if MRI is contraindicated\n- Determine if imaging findings are consistent with meningioma\n- If findings are consistent with meningioma, refer to Neurosurgery or Neurology\n\n### C. Treatment Candidacy Determination\n- Multidisciplinary evaluation to determine if patient is a candidate for treatment\n- If NOT a candidate for treatment \u2192 Implement surveillance protocol\n  - Monitor for changes in tumor size or symptoms\n  - Requires discussion through local tumor board or National TeleOncology CNS Virtual Tumor Board\n- If candidate for treatment \u2192 Proceed with appropriate treatment pathway\n\n## II. Treatment Decision Pathway\n\n### A. Surgical Management Assessment\n- Evaluate if patient is a candidate for surgical resection\n  - Consider tumor location, size, patient comorbidities, and functional status\n- If candidate for surgery \u2192 Proceed to surgical resection\n  - Post-resection MRI timing per neurosurgeon discretion\n- If not a candidate for surgery \u2192 Refer to Radiation Oncology and Neuro-oncology\n\n### B. Pathological Evaluation\n- Confirm meningioma diagnosis\n- WHO classification grading\n- Molecular testing (see Section IV)\n  - TERT mutation testing \n  - FISH for 22q/CDKN2A/B\n- Neuropathology consultation recommended for morphologically challenging cases\n- Simpson Grade evaluation of resection extent:\n  - Grades 1-3: Gross total resection\n  - Grades 4-5: Subtotal resection\n\n### C. Post-Surgical Management Based on WHO Classification\n\n#### 1. WHO Grade 1\n- **Assessment for residual tumor**:\n  - If residual tumor present \u2192 Refer to Radiation Oncology\n  - If no residual tumor \u2192 MRI surveillance protocol\n\n#### 2. WHO Grade 2\n- Refer to Radiation Oncology\n- **Assessment for residual tumor**:\n  - If residual tumor present \u2192 Adjuvant radiotherapy\n  - If no residual tumor \u2192 Patient preference between:\n    * Adjuvant radiotherapy, OR\n    * MRI surveillance\n\n#### 3. WHO Grade 3\n- Refer to Radiation Oncology for radiotherapy planning\n- Refer to Neuro-oncology for systemic therapy consideration\n- Consider referral to clinical trials\n\n## III. Monitoring and Follow-up\n\n### A. Surveillance Protocol for WHO Grade 1 without residual disease\n- MRI brain with and without contrast at regular intervals\n- Monitoring for symptomatic and/or MRI interval changes\n- Surveillance interval may increase after 5 years without tumor recurrence\n\n### B. Follow-up for patients receiving radiation therapy\n- Per Radiation Oncology protocol\n- Regular imaging assessment for treatment response and radiation effects\n\n### C. Follow-up for patients receiving systemic therapy\n- Per Neuro-oncology protocol\n- Regular assessment of treatment response and toxicity monitoring\n\n## IV. Molecular Testing Protocol\n\n### A. Patient Eligibility\n- **Patient Population**: All patients with meningioma\n- **Histology Requirement**: Any histology type is eligible for testing\n\n### B. Specimen Requirements\n- Tumor tissue required for all molecular testing\n\n### C. Testing Algorithm\n1. **TERT promoter mutation testing** - Standard for all meningiomas\n2. **Chromosomal analysis** - Choose ONE of the following options:\n   - **FISH Analysis** (preferred in most scenarios)\n     - Test target: CDKN2A/B homozygous loss\n   - **Microarray Analysis** (alternative when broader assessment needed)\n     - Test type: Chromosomal microarray (Oncoscan FFPE)\n\n### D. Interpretation and Clinical Significance\n- TERT mutation: Associated with aggressive behavior and higher recurrence risk\n- CDKN2A/B loss: Associated with aggressive behavior\n- Chromosome 22q loss: Common in meningiomas\n\n### E. Vendor Selection\n- Local VA or locally contracted vendor recommended for all testing types\n\n## V. Special Considerations\n\n### A. Clinical Trials\n- Clinical trials should always be considered as a treatment option\n- For assistance finding a clinical trial, email CancerClinicalTrials@va.gov\n\n### B. Multidisciplinary Care\n- Complex cases should be discussed at tumor boards\n- National TeleOncology CNS Virtual Tumor Board available for consultation\n- Referral to Neuro-oncology via National TeleOncology consult if local VA Neuro-oncology unavailable\n\n### C. VA Disability Benefits Eligibility (Presumptive Service Connection)\n1. **Atomic Veterans Exposed to Ionizing Radiation**\n   - Cancer of the brain (including meningioma) is presumptively service-connected\n\n2. **Gulf War and Post 9/11 Veterans**\n   - Eligible if served on/after September 11, 2001 in:\n     * Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, Yemen\n   - OR if served in Southwest Asia theater of operations or Somalia on/after August 2, 1990\n     * Southwest Asia theater includes: Iraq, Kuwait, Saudi Arabia, the neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, UAE, Oman, Gulf of Aden, Gulf of Oman, Persian Gulf, Arabian Sea, Red Sea, and airspace above these locations\n\nThis comprehensive structure integrates all the information provided from the different pages into a logical, clinically-oriented pathway document. It maintains focus on the clinical management aspects while also including the VA-specific information on presumptive conditions."
  }
}